// App-Quantinova.ai

4072 : Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Shukui Qin

Principal Investigators

  • Ho Yeong Lim

  • Baek-Yeol Ryoo

  • Cindy Li

  • Wenfeng Chen

  • Ann-Lii Cheng

Medical Centers

  • Medical Oncology Department, Nanjing Bayi Hospital, Nanjing, China

  • Merck Serono Pharmaceutical R&D Co., Ltd., Beijing, China

  • National Taiwan University Hospital, Taipei City, Taiwan

Locations

  • China

  • Taiwan

Companies

  • Merck Serono Co., Lt

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Encephalopathy

  • Solid malignancies

Biomarkers

  • Hepatocyte growth factor receptor

Drug/Treatment

  • Tepotinib

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • NA

Study Id's

  • NCT01988493

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved